Compare SBS & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SBS | UTHR |
|---|---|---|
| Founded | 1954 | 1996 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3B | 22.5B |
| IPO Year | 2002 | 1999 |
| Metric | SBS | UTHR |
|---|---|---|
| Price | $5.49 | $520.71 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $567.57 |
| AVG Volume (30 Days) | ★ 5.4M | 352.9K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | ★ 13.07 |
| EPS | N/A | ★ 5.82 |
| Revenue | N/A | ★ $1,483,300,000.00 |
| Revenue This Year | N/A | $6.39 |
| Revenue Next Year | $16.85 | $14.18 |
| P/E Ratio | ★ $15.19 | $90.09 |
| Revenue Growth | N/A | ★ 2.38 |
| 52 Week Low | $5.21 | $287.65 |
| 52 Week High | $35.79 | $609.35 |
| Indicator | SBS | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 36.31 | 36.10 |
| Support Level | $5.23 | $464.92 |
| Resistance Level | $5.68 | $542.66 |
| Average True Range (ATR) | 0.14 | 11.79 |
| MACD | 0.09 | -0.93 |
| Stochastic Oscillator | 35.00 | 7.63 |
Companhia De Saneamento Basico Do Estado De Sao Paulo is engaged in the provision of basic and environmental sanitation services in Sao Paulo State, and supplies treated water and sewage services on a wholesale basis. SABESP may perform activities in other states and countries and can operate in drainage, urban cleaning, solid waste handling, and energy markets. The company determined that it has a single operating segment, which is the provision of sanitation services.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.